Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchAndrographolideAndrographol.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study

Li et al., Antiviral Therapy, doi:10.1177/13596535241259952
Jun 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro study showing that andrographolide downregulates ACE2 expression and inhibits SARS-CoV-2 pseudovirus infection in a dose-dependent manner in human cells. Authors constructed a screening platform with a dual-luciferase reporter vector controlled by the ACE2 promoter. Out of 37 Chinese traditional medicinal herb compounds screened, andrographolide dose-dependently inhibited ACE2 transcription in HEK293T cells. RT-qPCR and Western blot confirmed andrographolide reduced ACE2 mRNA and protein expression in BEAS-2B bronchial epithelial cells. Pseudovirus assays demonstrated andrographolide inhibited SARS-CoV-2 infection in BEAS-2B cells.
22 preclinical studies support the efficacy of andrographolide for COVID-19:
Li et al., 14 Jun 2024, peer-reviewed, 8 authors. Contact: flong01@163.com, wentaoguo@126.com.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperAndrographol..All
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study
Qing Li, Hongmei Lu, Yongdui Ruan, Yuxuan Geng, Zuguo Zhao, Ying Liu, Long Feng, Wentao Guo
Antiviral Therapy, doi:10.1177/13596535241259952
Angiotensin-converting enzyme 2 (ACE2) is the receptor that enables SARS-CoV-2 to invade host cells. Previous studies have reported that reducing ACE2 expression may have an anti-SARS-CoV-2 effect. In this study, we constructed a pGL4.10-F2-ACE2 vector with double luciferase genes (firefly and Renilla luciferase) under the control of the ACE2 promoter and used it to screen compounds from Chinese traditional medicinal herbs (CTMHs) that can inhibit ACE2 transcription in human cells. We transfected HEK293T cells with pGL4.10-F2-ACE2 and treated them with CTMH compounds and then measured fluorescence to evaluate the indirect inhibition of ACE2 transcription. Out of 37 compounds tested, andrographolide demonstrated a dose-dependent inhibition of ACE2 transcription. We further confirmed by RT-qPCR and Western blot assays that andrographolide also reduced ACE2 expression in BEAS-2B cells in a dosedependent manner. Moreover, pseudovirus infection assays in BEAS-2B cells demonstrated that andrographolide can inhibit SARS-CoV-2 infection in a dose-dependent manner. These results suggest that andrographolide has potential anti-SARS-CoV-2 activity and could be a candidate drug for COVID-19 prevention and treatment.
Author Contributions YG and HL participated in the experiments, collated data, visualized data, and performed statistical analysis. YR and LF reviewed the manuscript and provided funding. DL was responsible for research oversight. GZ and YL provided suggestions and ideas for manuscript writing. LF and WG contributed to research execution, management, and coordination. All authors contributed to the article and approved the final manuscript version. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received funding support from several sources, including the Guangdong Provincial Medical Science and Technology Research Fund Project (A2021440), the Guangdong Provincial Bureau of Traditional Chinese Medicine Scientific Research Project (20211220), the Social Science Development Project of Dongguan City (20211800905542), the Guangdong Medical University Scientific Research Project (GDMUQ2021005), and the Discipline Construction Project of Guangdong Medical University (4SG21229GDGFY01). ORCID iD Wentao Guo  https://orcid.org/0000-0002-6194-5687 Supplemental Material Supplemental material for this article is available online.
References
An, Zhang, Duan, The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19, Biomed Pharmacother
Brevini, Maes, Webb, FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2, Nature
Chen, Xue, Ye, Activity of andrographolide and its derivatives against influenza virus in Vivo and in Vitro, Biol Pharm Bull
Chuerduangphui, Nukpook, Pientong, Activity of 3,19-isopropylidinyl andrographolide against herpes simplex virus type 1 in an animal model, Antivir Chem Chemother
Daina, Michielin, Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci Rep
Das, Das, Swain, Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: an in silico study, Future Virol
Edwin, Vasantha-Srinivasan, Senthil-Nathan, Anti-dengue efficacy of bioactive andrographolide from Andrographis paniculata (Lamiales: Acanthaceae) against the primary dengue vector Aedes aegypti (Diptera: Culicidae), Acta Trop
Feng, Lu, Ma, A novel dual-luciferase assay for anti-HIV drug screening based on the CCR5/ CXCR4 promoters, J Virol Methods
Hao, Lv, Xu, Andrographolide: synthetic methods and biological activities, Mini Rev Med Chem
Hossain, Urbi, Karuniawati, Andrographis paniculata (Burm. f.) Wall. ex Nees: An updated review of phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy, Life
Hu, Guo, Zhou, Characteristics of SARS-CoV-2 and COVID-19, Nat Rev Microbiol
Huang, Zhang, Zhang, Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms, Pharmacol Ther
Ivanov, Goc, Ivanova, Inhibition of ACE2 expression by ascorbic acid alone and its combinations with other natural compounds, Infect Dis (Auckl)
Lee, Tseng, Young, Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells, Br J Pharmacol
Li, Grant, Richards, ACE2 as therapeutic agent, Clin Sci (Lond)
Malat, Ekalaksananan, Heawchaiyaphum, Andrographolide inhibits Epstein-Barr virus lytic reactivation in EBV-positive cancer cell lines through the modulation of epigenetic-related proteins, Molecules
Martellucci, Flacco, Cappadona, SARS-CoV-2 pandemic: an overview, Adv Biol Regul
Navya, Hosur, A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection, Inform Med Unlocked
Nie, Li, Wu, Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2, Emerg Microbes Infect
Ou, Liu, Lei, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat Commun
Patil, Jain, Andrographolide: a review of analytical methods, Journal of Chromatographic Science
Sarker, Panigrahi, Hardy, Glucocorticoids bind to SARS-CoV-2 S1 at multiple sites causing cooperative inhibition of SARS-CoV-2 S1 interaction with ACE2, Front Immunol
Seniya, Shrivastava, Singh, Analyzing the interaction of a herbal compound andrographolide from andrographis paniculata as a folklore against swine flu (H1N1), Asian Pac J Trop Dis
Shi, Huang, Chen, Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage, Biochem Biophys Res Commun
Wan, Li, Liao, Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, Sci Rep
Wrapp, Wang, Corbett, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science
Wu, Dong, Chi, Traditional Chinese Medicine as a complementary therapy in combat with COVID-19-a review of evidence-based research and clinical practice, J Adv Nurs
Yang, Islam, Wang, Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective, Int J Biol Sci
Zalpoor, Bakhtiyari, Shapourian, Hesperetin as an anti-SARS-CoV-2 agent can inhibit COVID-19-associated cancer progression by suppressing intracellular signaling pathways, Inflammopharmacol
Zeng, Wei, Zhou, Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches, Phytother Res
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
{ 'indexed': {'date-parts': [[2024, 6, 15]], 'date-time': '2024-06-15T00:29:02Z', 'timestamp': 1718411342720}, 'reference-count': 31, 'publisher': 'SAGE Publications', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2024, 6, 1]], 'date-time': '2024-06-01T00:00:00Z', 'timestamp': 1717200000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ { 'name': 'Guangdong Provincial Medical Science and Technology Research Fund Project', 'award': ['A2021440']}, { 'name': 'Guangdong Provincial Bureau of Traditional Chinese Medicine Scientific Research ' 'Project', 'award': ['20211220']}, { 'name': 'Discipline Construction Project of Guangdong Medical University', 'award': ['4SG21229GDGFY01']}, {'name': 'Guangdong Medical University Scientific Research Project', 'award': ['GDMUQ2021005']}, {'name': 'Social Science Development Project of Dongguan City', 'award': ['20211800905542']}], 'content-domain': {'domain': ['journals.sagepub.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2024, 6]]}, 'abstract': '<jats:p> Angiotensin-converting enzyme 2 (ACE2) is the receptor that enables SARS-CoV-2 to ' 'invade host cells. Previous studies have reported that reducing ACE2 expression may have an ' 'anti-SARS-CoV-2 effect. In this study, we constructed a pGL4.10-F2-ACE2 vector with double ' 'luciferase genes (firefly and Renilla luciferase) under the control of the ACE2 promoter and ' 'used it to screen compounds from Chinese traditional medicinal herbs (CTMHs) that can inhibit ' 'ACE2 transcription in human cells. We transfected HEK293T cells with pGL4.10-F2-ACE2 and ' 'treated them with CTMH compounds and then measured fluorescence to evaluate the indirect ' 'inhibition of ACE2 transcription. Out of 37 compounds tested, andrographolide demonstrated a ' 'dose-dependent inhibition of ACE2 transcription. We further confirmed by RT-qPCR and Western ' 'blot assays that andrographolide also reduced ACE2 expression in BEAS-2B cells in a ' 'dose-dependent manner. Moreover, pseudovirus infection assays in BEAS-2B cells demonstrated ' 'that andrographolide can inhibit SARS-CoV-2 infection in a dose-dependent manner. These ' 'results suggest that andrographolide has potential anti-SARS-CoV-2 activity and could be a ' 'candidate drug for COVID-19 prevention and treatment. </jats:p>', 'DOI': '10.1177/13596535241259952', 'type': 'journal-article', 'created': {'date-parts': [[2024, 6, 14]], 'date-time': '2024-06-14T10:18:38Z', 'timestamp': 1718360318000}, 'update-policy': 'http://dx.doi.org/10.1177/sage-journals-update-policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic ' 'study', 'prefix': '10.1177', 'volume': '29', 'author': [ { 'given': 'Qing', 'family': 'Li', 'sequence': 'first', 'affiliation': [ { 'name': 'The First Dongguan Affiliated Hospital, Guangdong Medical ' 'University, Donguan, China'}, { 'name': 'Department of Pathogenic Organism Biology, Henan University of ' 'Chinese Medicine, Zhengzhou, China'}]}, { 'given': 'Hongmei', 'family': 'Lu', 'sequence': 'additional', 'affiliation': [ { 'name': 'The First Dongguan Affiliated Hospital, Guangdong Medical ' 'University, Donguan, China'}]}, { 'given': 'Yongdui', 'family': 'Ruan', 'sequence': 'additional', 'affiliation': [ { 'name': 'The First Dongguan Affiliated Hospital, Guangdong Medical ' 'University, Donguan, China'}]}, { 'given': 'Yuxuan', 'family': 'Geng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pathogenic Organism Biology, Henan University of ' 'Chinese Medicine, Zhengzhou, China'}]}, { 'given': 'Zuguo', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Basic Medicine, Guangdong Medical University, Donguan, ' 'China'}]}, { 'given': 'Ying', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacy, DongGuan SongShan Lake Tung Wah ' 'Hospital, DongGuan, China'}]}, { 'given': 'Long', 'family': 'Feng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pathogenic Organism Biology, Henan University of ' 'Chinese Medicine, Zhengzhou, China'}]}, { 'ORCID': 'http://orcid.org/0000-0002-6194-5687', 'authenticated-orcid': False, 'given': 'Wentao', 'family': 'Guo', 'sequence': 'additional', 'affiliation': [ { 'name': 'The First Dongguan Affiliated Hospital, Guangdong Medical ' 'University, Donguan, China'}, { 'name': 'School of Basic Medicine, Guangdong Medical University, Donguan, ' 'China'}]}], 'member': '179', 'published-online': {'date-parts': [[2024, 6, 14]]}, 'reference': [ { 'key': 'bibr1-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-020-00459-7'}, { 'key': 'bibr2-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jbior.2020.100736'}, { 'key': 'bibr3-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2012-7'}, { 'key': 'bibr4-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abb2507'}, { 'key': 'bibr5-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2021.111267'}, { 'key': 'bibr6-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/life11040348'}, { 'key': 'bibr7-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.actatropica.2016.07.009'}, { 'key': 'bibr8-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2222-1808(14)60692-7'}, { 'key': 'bibr9-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bph.12440'}, { 'key': 'bibr10-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1248/bpb.32.1385'}, { 'key': 'bibr11-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/molecules27144666'}, { 'key': 'bibr12-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/20402066221089724'}, { 'key': 'bibr13-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.2217/fvl-2021-0171'}, { 'key': 'bibr14-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbrc.2020.08.086'}, { 'key': 'bibr15-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jviromet.2018.02.016'}, { 'key': 'bibr16-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-15562-9'}, { 'key': 'bibr17-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep42717'}, { 'key': 'bibr18-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/CS20200570'}, { 'key': 'bibr19-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.imu.2021.100714'}, { 'key': 'bibr20-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2022.906687'}, { 'key': 'bibr21-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-022-05594-0'}, { 'key': 'bibr22-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.7150/ijbs.45538'}, { 'key': 'bibr23-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jan.14673'}, { 'key': 'bibr24-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pharmthera.2021.107843'}, { 'key': 'bibr25-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1178633721994605'}, { 'key': 'bibr26-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10787-022-01054-3'}, { 'key': 'bibr27-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-024-54722-5'}, { 'key': 'bibr28-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ptr.7324'}, { 'key': 'bibr29-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/chromsci/bmaa091'}, { 'key': 'bibr30-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1389557520666200429100326'}, { 'key': 'bibr31-13596535241259952', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/22221751.2020.1743767'}], 'container-title': 'Antiviral Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/13596535241259952', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journals.sagepub.com/doi/full-xml/10.1177/13596535241259952', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/13596535241259952', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 6, 14]], 'date-time': '2024-06-14T10:18:53Z', 'timestamp': 1718360333000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.sagepub.com/doi/10.1177/13596535241259952'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 6]]}, 'references-count': 31, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2024, 6]]}}, 'alternative-id': ['10.1177/13596535241259952'], 'URL': 'http://dx.doi.org/10.1177/13596535241259952', 'relation': {}, 'ISSN': ['1359-6535', '2040-2058'], 'subject': [], 'container-title-short': 'Antiviral Therapy', 'published': {'date-parts': [[2024, 6]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit